



NDA 21-980

Alcon Research, Ltd.
Attention: Terry J. Dagnon
Associate Director, Regulatory Affairs
6201 South Freeway, R7-18
Fort Worth, TX 76134-2099

Dear Mr. Dagnon:

Please refer to your new drug application (NDA) dated September 28, 2005, received September 29, 2005, submitted under section 505(b)/pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Fluorescite® (fluorescein injection, USP) 10%.

We acknowledge receipt of your submissions dated November 2, 2005, and January 13, and 30, February 15, 20, and 23, and March 10, 16, 20, and 23, 2006.

This new drug application provides for the use of Fluorescite® (fluorescein injection, USP) 10% in diagnostic fluorescein angiography or angiography of the retina and iris vasculature.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the labeling submitted on March 23, 2006 (text for the package insert) and March 16, 2006 (text for immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have completed the pediatric study requirement for this application.

The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999) and *Providing Regulatory Submissions in Electronic Format – Content of Labeling* (February 2004). The guidances specify that labeling to be submitted in *pdf* format. Please submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDA*. Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Infective and Ophthalmology Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective and Ophthalmology
Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosures: Package Insert, Carton and Container Labels

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth
3/28/2006 03:17:48 PM